Genitourinary syndrome of menopause therapy widens past systemic hormone therapy
Vaginal estrogen formulation maturity, ospemifene and prasterone uptake, and emerging non-hormonal mechanism programs are restructuring genitourinary syndrome of menopause management.
Genitourinary syndrome of menopause (GSM) was historically managed as a systemic-hormone-therapy or local-vaginal-estrogen category. Vaginal estrogen formulations have multiple options (cream, ring, tablet, insert), ospemifene provides an oral non-estrogen option, prasterone provides an intravaginal DHEA option, and emerging non-hormonal mechanism programs are reading out. The breast cancer survivor population is a particular use case for the non-systemic options.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.